The responsible transport gene that allows the production of lemon acid in large quantities was recently discovered. A breakthrough!
The complex tumour structure makes the treatment of breast cancer a medical challenge. A promising, novel selenium-based breast cancer nanoparticle therapy, which is topic of the EU-project Neosetac, could change that: It has proved to boost the active agent delivery and assure it’s active only in the target tissue while also bringing the suggestion of reduced side effects. The project findings are expected to increase the efficiency of future chemotherapies and prevent recurrence of the cancer after complete remission.
Have you ever wondered, why it often takes many years until a new drug is available at your local pharmacy? One of the reasons is that the pharmaceutical industry wants to make sure that the drug is not only effective but also doesn’t produce toxic breakdown products that lead to undesireable side effects. Therefore, many time-consuming and not seldomly expensive tests are required to know precisely, which possible metabolic by-products could emerge. In a next step, the industry is producing such derivates to test them thoroughly for their side-effects, ensuring one goal: the patients health and wellbeing.
Biosensors may soon facilitate the analysis of a patient’s entire red blood cell antigen repertoire. In the form of diagnostic test strips, they could make the analysis swift and location-independent. This could have enormous potential not only in medical diagnosis, but also for environmental analysis if extended to other analytes.
More than 32 Million tons of plastic waste end up in our environment per year. Most of it is non-degradable polyethylene, produced from about 8% of the global mineral oil resources. Researchers of the Austrian Centre of Industrial Biotechnology develop new biotechnological solutions to substitute critical processes. In the EU-funded project ROBOX, acib’s partners Uni Maastricht and Chemstream from Belgium have developed an approach to produce polyethylene biologically and sustainably from plant extracts. Enzyme-engineering can help to produce plastic without the use of harmful solvents.
Pink, fat and healthy – that’s how we visualize the ideal pig. But what if Pink Beauty’s stomach is upset? There can be a range of consequences from stress to enteritis, from reduced fattening performance for the industry to a decline of meat quality for the consumer. In a recent survey conducted by the Austrian Centre of Industrial Biotechnology (acib), University of Natural Resources and Life Sciences (BOKU) and IPUS GmbH Rottenmann, scientists sort to find out how acidification during feed digestion can be managed and which natural feed additives support animal health and welfare.
Co-author: Sabrina Mayer-Maschl
On Friday, April 13th 2018, it was time to experience the world of science and research! Despite the not very promising date, the organizers expected a large number of visitors to come. During the 8th Long Night of Research, Austria’s largest nationwide research event, current science projects, new findings and technologies were presented in understandable and entertaining ways. With 228.000 visitors a new record was achieved. This shows the steadily growing interest in the research topics of the future.
Many bio-plastic bags have no place in the garbage. They dissolve too slowly in oxygen-deficient environments like biogas plants and when incinerated they are a burden to the environment. Enzymes offer a solution to this problem, accelerating degradation and avoid emissions. In the long run, the aim is to reduce plastic mountains and replace conventional packaging by bio-based Polymers.
There are a multitude of challenges associated with the production of next-generation biopharmaceuticals and vaccines. To be effective as a public health tool, vaccines for example are increasingly administered in form of a combination of more than one component and produced in large scale by means of seed viruses. These are living pathogens that multiply in cells from chicken eggs. The rule of thumb “one vaccine dose per egg” means that the number of vaccines is limited to 150 to 200 million available eggs worldwide. Formerly used alternative platforms – such as vaccine production in cell cultures (e.g. mammalian cells) – also have the disadvantage of instability. A new platform technology for the production of the most diverse proteins in an optimised process could be the answer.